A phase II multicentric trial to assess efficacy and toxicity of imatinib in adult patients with metastatic ocular melanoma

Trial Profile

A phase II multicentric trial to assess efficacy and toxicity of imatinib in adult patients with metastatic ocular melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Cancer metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 10 Aug 2012 Actual end date (1 Mar 2007) added as reported by ClinicalTrials.gov.
    • 01 Mar 2007 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top